Goal 2: Reduce Human Disease

Funding Limitations Block Intervention Research

The cap on R01 research grants at $500,000 per year has not changed in over 20 years. In the current fiscal crisis for research it has become an immovable block to submitting intervention studies (randomized clinical trials on treatment). Routine advice from NIH staff is to not even try for a larger study. The cap applies to every year, so one can design a trial that costs less than $2.5 million but exceeds $500,000 in ...more »

Submitted by (@stephen.fortmann)

Voting

3 net votes
6 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

Clinical Research for HIV/AIDS and HLB Health and Diseases

What HIV/AIDS-related clinical research can NHLBI support in the next 5-10 years on the prevention, diagnosis, and treatment of HIV-related heart, lung, and/or blood (HLB) diseases in adults and children to improve heart, lung, and blood health outcomes in HIV infections?

Submitted by (@nhlbiforumadministrator1)

Voting

-19 net votes
14 up votes
33 down votes
Active

Goal 2: Reduce Human Disease

Shift from NHLBI guided research to individual investigator initiative

NHLBI directed research should be abandoned and switched to investigator initiated research. I respectfully suggest read the following assay by Brown and Goldstein, Science 2012; 338: 1033-1034 The best way to run the science sponsored by the NIH (or NHLBI) is not to guide it (analogy to running science from ivory tower) but let the investigators decide what is worth pursuing. Get rid of NHLBI-directed research initiative ...more »

Submitted by (@nhlbiforumadministrator)

Voting

47 net votes
63 up votes
16 down votes
Active

Goal 2: Reduce Human Disease

Basic Research for HIV/AIDS and HLB Health and Diseases

What HIV/AIDS-related basic research can NHLBI support in the next 5-10 years to investigate the fundamental mechanisms of HIV-related heart, lung, and/or blood (HLB) diseases alone and in the context of antiretroviral therapy (ART) to improve heart, lung, and blood health outcomes in HIV infections as well as the fundamental mechanisms of hematopoietic stem cell transplantation in potential elimination or eradication ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

-22 net votes
14 up votes
36 down votes
Active

Goal 2: Reduce Human Disease

Pick Me, Pick Me! The Challenges of Being at the Mercy of a Few

One significant challenge if you're a patient or a patient advocate is "who is going to find a life-saving treatment or cure for my disease. Who is going to Pick me and my disease?". The answer is complex but lies within the research community's priorities and interests. Think for a moment like a patient. You are at the mercy of the research community at large, government agencies and companies willing to make your ...more »

Submitted by (@teresabarnes)

Voting

-3 net votes
1 up votes
4 down votes
Active

Goal 2: Reduce Human Disease

The potency and safety of transfusable red blood cells

Can we identify approaches to improve potency and/or safety of transfusable RBCs? 42 day pre-transfusion storage of RBCs maximizes utilization, while minimizing waste. However, RBCs undergo changes during collection, manipulation and storage that may reduce their potency or safety. Progress in understanding markers that predict transfusion success at the time of collection and with storage remains slow. New technologies ...more »

Submitted by (@nareg.roubinian)

Voting

14 net votes
31 up votes
17 down votes
Active